309 related articles for article (PubMed ID: 34376758)
1. Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population.
Agrawal C; Goyal P; Agarwal A; Tripathi R; Dodagoudar C; Baghmar S; Sharma A; Batra U; Talwar V; Goyal S; Kumar R; Doval DC
Sci Rep; 2021 Aug; 11(1):16236. PubMed ID: 34376758
[TBL] [Abstract][Full Text] [Related]
2. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
DeMichele A; Cristofanilli M; Brufsky A; Liu X; Mardekian J; McRoy L; Layman RM; Emir B; Torres MA; Rugo HS; Finn RS
Breast Cancer Res; 2021 Mar; 23(1):37. PubMed ID: 33761995
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
[TBL] [Abstract][Full Text] [Related]
5. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China.
Liu C; Li T; Tao Z; Cao J; Wang L; Zhang J; Wang B; Hu X
Med Sci Monit; 2020 Nov; 26():e927187. PubMed ID: 33250509
[TBL] [Abstract][Full Text] [Related]
7. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.
Jiang H; Zhong J; Wang J; Song G; Di L; Shao B; Zhang R; Liu Y; Zhu A; Wang N; Li H
Cancer Med; 2024 May; 13(10):e7249. PubMed ID: 38770648
[TBL] [Abstract][Full Text] [Related]
8. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
9. Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study.
Mycock K; Zhan L; Hart K; Taylor-Stokes G; Milligan G; Atkinson C; Mitra D
Future Oncol; 2022 Jan; 18(3):349-362. PubMed ID: 34842454
[TBL] [Abstract][Full Text] [Related]
10. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
Mayer EL; Ren Y; Wagle N; Mahtani R; Ma C; DeMichele A; Cristofanilli M; Meisel J; Miller KD; Abdou Y; Riley EC; Qamar R; Sharma P; Reid S; Sinclair N; Faggen M; Block CC; Ko N; Partridge AH; Chen WY; DeMeo M; Attaya V; Okpoebo A; Alberti J; Liu Y; Gauthier E; Burstein HJ; Regan MM; Tolaney SM
J Clin Oncol; 2024 Jun; 42(17):2050-2060. PubMed ID: 38513188
[TBL] [Abstract][Full Text] [Related]
11. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Walker AJ; Wedam S; Amiri-Kordestani L; Bloomquist E; Tang S; Sridhara R; Chen W; Palmby TR; Fourie Zirkelbach J; Fu W; Liu Q; Tilley A; Kim G; Kluetz PG; McKee AE; Pazdur R
Clin Cancer Res; 2016 Oct; 22(20):4968-4972. PubMed ID: 27407089
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib combined with endocrine therapy in heavily pretreated HR
Manso L; Hernando C; Galán M; Oliveira M; Cabrera MA; Bratos R; Rodríguez CA; Ruiz-Borrego M; Blanch S; Llombart-Cussac A; Delgado-Mingorance JI; Álvarez-Busto I; Gallegos I; González-Cortijo L; Morales S; Aguirre E; Hernando BA; Ballesteros A; Alés-Martínez JE; Reboredo C; Oltra A; González-Cao M; Santisteban M; Malón D; Echeverría I; García-Garre E; Vega E; Servitja S; Andrés R; Robles CE; López R; Galve E; Echarri MJ; Legeren M; Moreno F
Breast; 2020 Dec; 54():286-292. PubMed ID: 33242755
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment.
Dhakal A; Matthews CM; Levine EG; Salerno KE; Zhang F; Takabe K; Early AP; Edge SB; O'Connor T; Khoury T; Young JS; Opyrchal M
Clin Breast Cancer; 2018 Dec; 18(6):e1401-e1405. PubMed ID: 29778787
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer.
Ban M; Miše BP; Majić A; Dražić I; Vrdoljak E
Future Oncol; 2018 Mar; 14(6):537-544. PubMed ID: 29164917
[TBL] [Abstract][Full Text] [Related]
16. Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.
Hoste G; Punie K; Wildiers H; Beuselinck B; Lefever I; Van Nieuwenhuysen E; Han SN; Berteloot P; Concin N; Salihi R; Vergote I; Neven P
Breast Cancer Res Treat; 2018 Aug; 171(1):131-141. PubMed ID: 29766363
[TBL] [Abstract][Full Text] [Related]
17. Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer.
Porte B; Carton M; Lerebours F; Brain E; Loirat D; Haroun L; Bellesoeur A; Bach Hamba S; Kirova Y; Cottu P
Breast; 2020 Dec; 54():303-310. PubMed ID: 33242757
[TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2- patients with metastatic breast cancer.
Li J; Zhang X; Yang C; Lv Y; Yang H; Kong X; Han M; Wang Z; Ma J; Han J; Liu Y
Medicine (Baltimore); 2021 Nov; 100(44):e27710. PubMed ID: 34871262
[TBL] [Abstract][Full Text] [Related]
19. Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer.
Xi J; Oza A; Thomas S; Ademuyiwa F; Weilbaecher K; Suresh R; Bose R; Cherian M; Hernandez-Aya L; Frith A; Peterson L; Luo J; Krishnamurthy J; Ma CX
J Natl Compr Canc Netw; 2019 Feb; 17(2):141-147. PubMed ID: 30787127
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice.
Rath S; Elamarthi P; Parab P; Gulia S; Nandhana R; Mokal S; Kembhavi Y; Perumal P; Bajpai J; Ghosh J; Gupta S
PLoS One; 2021; 16(7):e0253722. PubMed ID: 34292933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
